论文部分内容阅读
目的分析多西紫杉醇联合替吉奥治疗蒽环类耐药晚期乳腺癌的临床疗效。方法选择2012年10月至2014年4月间湖南省肿瘤医院收治的112例蒽环类耐药晚期乳腺癌患者,采用随机数字表法随机分为治疗组和对照组,每组各56例。治疗组患者应用多西紫杉醇联合替吉奥治疗,对照组患者应用长春瑞滨联合顺铂治疗。治疗6周后,比较两组患者的疗效。结果治疗组患者的总有效率和临床收益率分别为57.1%和83.9%,与对照组比较,差异均无统计学意义(均P>0.05)。治疗组患者的1年生存率高于对照组,差异有统计学意义(P<0.05);两组患者的2年生存率比较,差异无统计学意义(P>0.05)。治疗组患者恶心呕吐的发生率低于对照组,差异有统计学意义(P<0.05);两组患者其他毒副反应发生率比较,差异无统计学意义(P>0.05)。结论多西紫杉醇联合替吉奥治疗蒽环类耐药晚期乳腺癌的临床疗效显著,具有临床推广价值。
Objective To analyze the clinical efficacy of docetaxel combined with tegaserod in the treatment of advanced anthracycline-resistant breast cancer. Methods One hundred and twelve patients with advanced anthracycline-resistant breast cancer who were admitted to Hunan Cancer Hospital from October 2012 to April 2014 were randomly divided into treatment group and control group with 56 cases in each group. Patients in the treatment group were treated with docetaxel in combination with tegaserod, and patients in the control group were treated with vinorelbine plus cisplatin. After 6 weeks of treatment, the efficacy of the two groups was compared. Results The total effective rate and clinical rate of return in the treatment group were 57.1% and 83.9%, respectively, which were not significantly different from those in the control group (all P> 0.05). The 1-year survival rate of the treatment group was higher than that of the control group, with significant difference (P <0.05). There was no significant difference in the 2-year survival rate between the two groups (P> 0.05). The incidence of nausea and vomiting in the treatment group was lower than that in the control group (P <0.05). There was no significant difference in the incidence of other toxic and side effects between the two groups (P> 0.05). Conclusions Docetaxel and tegaserod are effective in the treatment of anthracycline-resistant advanced breast cancer and have clinical value.